Search

Your search keyword '"Morelli, F."' showing total 761 results
Start Over Author "Morelli, F."
761 results on '"Morelli, F."'

5. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Author

Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., and Sternberg, C.N.

Published
2021
Full Text
View/download PDF

6. Ne bis in idem: nozione, spazi operativi e rimedi

Author

Cabiale, A, Camaldo, LBC, Colaiacovo, G, Della Torre, J, La Rocca, EN, Maggio, P, Mangiaracina, A, Miraglia, M, Morelli, F, Nacar, B, Nicolicchia, F, Parlato, L, Sanna, A, Zacchè, F, Zacche', F, Cabiale, A, Camaldo, LBC, Colaiacovo, G, Della Torre, J, La Rocca, EN, Maggio, P, Mangiaracina, A, Miraglia, M, Morelli, F, Nacar, B, Nicolicchia, F, Parlato, L, Sanna, A, Zacchè, F, and Zacche', F

Published
2024

10. PROSTATIC ARTERY EMBOLIZATION IN PATIENTS WITH INDWELLING BLADDER CATHETER.

Author

Secco, S, primary, Campobasso, D, additional, Guarino, G, additional, Maggiorelli, S, additional, Brambillasca, P, additional, De Cinque, A, additional, Paladini, I, additional, Andreone, A, additional, Morelli, F, additional, Olivero, A, additional, Favali, M, additional, Zagnoli, A, additional, Dell’Oglio, P, additional, Ferretti, S, additional, Di Chiacchio, G, additional, Ziglioli, F, additional, Patera, A, additional, Slawitz, M, additional, Di Marco, G, additional, Puliatti, S, additional, Micali, S, additional, Bocciardi, A, additional, Rampoldi, A, additional, Maestroni, U, additional, and Galfano, A, additional

Published
2023
Full Text
View/download PDF

14. Portal Steal Syndrome From a Large Linton’s Splenorenal Shunt after Liver Transplantation: Successful Endovascular Management Through Off-Label Application of a 30 mm Amplatzer Cardiac Plug

Author

Centonze, L, Vella, I, Morelli, F, Checchini, G, De Carlis, R, Rampoldi, A, Lauterio, A, Andorno, E, De Carlis, L, Centonze L., Vella I., Morelli F., Checchini G., De Carlis R., Rampoldi A., Lauterio A., Andorno E., De Carlis L., Centonze, L, Vella, I, Morelli, F, Checchini, G, De Carlis, R, Rampoldi, A, Lauterio, A, Andorno, E, De Carlis, L, Centonze L., Vella I., Morelli F., Checchini G., De Carlis R., Rampoldi A., Lauterio A., Andorno E., and De Carlis L.

Abstract

A 34-year-old patient underwent liver transplantation for progressive hepatic failure in the setting of congenital hepatic fibrosis. In past medical history, the patient had undergone splenectomy with proximal Linton’s splenorenal surgical shunt creation for symptomatic portal hypertension with hypersplenism. The patient developed an early allograft dysfunction, with radiologic evidence of a reduced portal flow associated to portal steal from the patent surgical shunt. The patient was successfully treated through endovascular placement of a 30 mm Amplatzer cardiac plug at the origin of the splenic vein.

Published
2022

16. Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience

Author

Innocenti, Idanna, Fresa, Alberto, Tomasso, Annamaria, Tarnani, Michela, De Padua, L., Benintende, G., Pasquale, R., Galli, Eugenio, Morelli, F., Giannarelli, Diana, Autore, Francesco, Laurenti, Luca, Innocenti I., Fresa A., Tomasso A., Tarnani M., Galli E., Giannarelli D., Autore F., Laurenti L. (ORCID:0000-0002-8327-1396), Innocenti, Idanna, Fresa, Alberto, Tomasso, Annamaria, Tarnani, Michela, De Padua, L., Benintende, G., Pasquale, R., Galli, Eugenio, Morelli, F., Giannarelli, Diana, Autore, Francesco, Laurenti, Luca, Innocenti I., Fresa A., Tomasso A., Tarnani M., Galli E., Giannarelli D., Autore F., and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Background: This monocentric retrospective study describes the treatment patterns and outcomes of chronic lymphocytic leukemia (CLL) patients. Methods: Adult CLL patients treated between 1992 and 2022 were included. The time to next treatment (TTNT) was defined as the time from the treatment’s start to the start of a subsequent therapy or death. The time to next treatment failure or death (TTNTF) was defined as the time from treatment discontinuation to the discontinuation of a subsequent therapy or death. Results: Of 637 registered patients, 318 (49.9%) received treatment. We evaluated 157 cBTKi-exposed, 34 BCL2i-exposed cBTKi-naïve, and 26 double-exposed patients. The five-year TTNT values in the cBTKi-exposed patients were 80% (median NR), 40% (median 40 months), and 21% (median 24 months) months in the first line (1L), second line (2L), and beyond the second line (>2L), respectively (p < 0.0001). The five-year TTNT values in the BCL2i-exposed patients were 83% (median NR), 72% (median NR), 12% (median 28 months) in the 1L, 2L, and >2L, respectively (p = 0.185). The median TTNTF was 9 months (range 1–87) after cBTKi and 17 months (range 8–49) after both a cBTKi and BCL2i. Conclusions: This study suggests that, in CLL patients, the earlier we used targeted therapies, the better was the outcome obtained. Nonetheless, the poor outcomes in the advanced lines of therapy highlight the need for more effective treatments.

Published
2023

20. Efficacy of prostate artery embolization in patients with indwelling bladder catheter

Author

Secco, S., primary, Brambillasca, P., additional, Morelli, M., additional, Sampogna, G., additional, Alfonsi, A., additional, Morelli, F., additional, Solcia, M., additional, Dell’Oglio, P., additional, Olivero, A., additional, Palagonia, E., additional, Spinelli, M., additional, Bocciardi, A., additional, Rampoldi, A., additional, and Galfano, A., additional

Published
2022
Full Text
View/download PDF

21. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Author

Tedeschi, A, Frustaci, A, Mauro, F, Chiarenza, A, Coscia, M, Ciolli, S, Reda, G, Laurenti, L, Varettoni, M, Murru, R, Barate, C, Sportoletti, P, Greco, A, Borella, C, Rossi, V, Deodato, M, Biagi, A, Zamprogna, G, Pelle, A, Lapietra, G, Vitale, C, Morelli, F, Cassin, R, Fresa, A, Cavalloni, C, Postorino, M, Ielo, C, Cairoli, R, Di Raimondo, F, Montillo, M, Del Poeta, G, Tedeschi A., Frustaci A. M., Mauro F. R., Chiarenza A., Coscia M., Ciolli S., Reda G., Laurenti L., Varettoni M., Murru R., Barate C., Sportoletti P., Greco A., Borella C., Rossi V., Deodato M., Biagi A., Zamprogna G., Pelle A. C., Lapietra G., Vitale C., Morelli F., Cassin R., Fresa A., Cavalloni C., Postorino M., Ielo C., Cairoli R., Di Raimondo F., Montillo M., Del Poeta G., Tedeschi, A, Frustaci, A, Mauro, F, Chiarenza, A, Coscia, M, Ciolli, S, Reda, G, Laurenti, L, Varettoni, M, Murru, R, Barate, C, Sportoletti, P, Greco, A, Borella, C, Rossi, V, Deodato, M, Biagi, A, Zamprogna, G, Pelle, A, Lapietra, G, Vitale, C, Morelli, F, Cassin, R, Fresa, A, Cavalloni, C, Postorino, M, Ielo, C, Cairoli, R, Di Raimondo, F, Montillo, M, Del Poeta, G, Tedeschi A., Frustaci A. M., Mauro F. R., Chiarenza A., Coscia M., Ciolli S., Reda G., Laurenti L., Varettoni M., Murru R., Barate C., Sportoletti P., Greco A., Borella C., Rossi V., Deodato M., Biagi A., Zamprogna G., Pelle A. C., Lapietra G., Vitale C., Morelli F., Cassin R., Fresa A., Cavalloni C., Postorino M., Ielo C., Cairoli R., Di Raimondo F., Montillo M., and Del Poeta G.

Abstract

Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability. In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes. Age did not independently influence survival and ibrutinib tolerance, indicating that not age per se, but age-related conditions, may affect drug management. We confirmed the role of CIRS . 6 as a predictor of a poorer progression- and event-free survival (PFS, EFS). The presence of a severe comorbidity was significantly associated with permanent dose reductions (PDRs), not translating into worse outcomes. As expected, del(17p) and/or TP53mut and previous therapies affected PFS, EFS, and overall survival. No study so far has analyzed the influence of concomitant medications and CYP3A inhibitors with ibrutinib. In our series, these factors had no impact, although CYP3A4 inhibitors use correlated with Cox regression analysis, with an increased risk of PDR. Despite the limitation of its retrospective nature, this large study confirmed the role of ECOG-PS as the most accurate predictor of ibrutinib feasibility and outcomes, and importantly, neutropenia emerged as a relevant tool influencing patients’ vulnerability. Although CIRS > 6 retained a significant impact on PFS and EFS, its value should be confirmed by prospective studies.

Published
2021

22. Trauma quality indicators: internationally approved core factors for trauma management quality evaluation

Author

Coccolini, F, Kluger, Y, Moore, E, Maier, R, Coimbra, R, Ordonez, C, Ivatury, R, Kirkpatrick, A, Biffl, W, Sartelli, M, Hecker, A, Ansaloni, L, Leppaniemi, A, Reva, V, Civil, I, Vega, F, Chiarugi, M, Chichom-Mefire, A, Sakakushev, B, Peitzman, A, Chiara, O, Abu-Zidan, F, Maegele, M, Miccoli, M, Chirica, M, Khokha, V, Sugrue, M, Fraga, G, Otomo, Y, Baiocchi, G, Catena, F, Kuliesius, Z, Conti, L, Dogjani, A, Lee, J, Consani, H, Russello, D, Bortul, M, Maurel, T, Kaf, H, Adamou, H, Alin, V, Robustelli, U, Sato, N, Seretis, C, Quiodettis, M, Gomes, C, Kong, V, Zakaria, A, Guner, A, Gachabayov, M, Chowdhury, S, Pata, F, Garcia, A, Rems, M, Das, K, Riedel, J, Lasithiotakis, K, Sydorchuk, R, Sydorchuk, L, Lostoridis, E, Buia, A, Mcfarlane, M, Ciani, R, Munoz-Cruzado, V, Tartaglia, D, Ioannidis, O, Muhrbeck, M, Reicher, M, Roscio, F, Ceresoli, M, Tsiftsis, D, Kavalakat, A, Pintar, T, Georgiou, G, Ricci, G, Mohan, R, Saar, S, Di Carlo, I, Isik, A, Ahmed, A, Gonsaga, R, Sammartano, F, Tallon-Aguilar, L, Shoko, T, Hsu, J, Kobe, Y, Romeo, C, Podda, M, Mingoli, A, Delgado, R, Ekwen, G, Aude, V, Olona, C, Boati, P, Magnone, S, Capaldi, M, Bala, M, Picetti, E, Negoi, I, Kok, K, Jusoh, A, Amato, B, Nita, G, de Beaux, A, Demetrashvili, Z, Davies, R, Kim, J, Pereira, A, Fattori, L, Paolillo, C, Ghannam, W, Rodriguez, F, Berardi, L, Florio, M, Hecker, M, Dubuisson, V, O'Connor, D, De'Angelis, N, Dobric, I, Massalou, D, Ortenwall, P, Pikoulis, E, Ugarte-Sierra, B, Zuidema, W, Kechagias, A, Marwah, S, Litvin, A, Nikolopoulos, I, Pesce, A, Uranues, S, Luppi, D, Flohe, S, Martinez-Perez, A, Lorenzo, M, Vergano, L, Manca, M, Malacarne, P, Kurihara, H, Widder, S, Pucciarelli, M, Monzani, F, Brambillasca, P, Corbella, D, Agresta, F, Moore, L, Buonomo, L, Adeleye, A, Kim, D, Veroux, M, Hardcastle, T, Di Saverio, S, Recordare, A, Rubio-Perez, I, Shlyapnikov, S, Rahim, R, Vega, G, Boris, K, Sawyer, R, Baraket, O, Soreide, K, Weber, C, Seak, C, Herman, S, Gamberini, E, Costa, S, Mazzocconi, G, Lozada, E, Manatakis, D, Lohsiriwat, V, Elbery, B, Tiberio, G, Santini, M, Mellace, L, Enoksen, C, Major, P, Parini, D, Improta, M, Fugazzola, P, Pini, S, Liberti, G, Martino, C, Cobianchi, L, Canzi, G, Cicuttin, E, Kenig, J, Zago, M, Giannessi, S, Scaglione, M, Orsitto, E, Cioni, R, Ghiadoni, L, Menichetti, F, Agnoletti, V, Sganga, G, Prosperi, P, Roviello, F, De Paolis, P, Gordini, G, Forfori, F, Ruscelli, P, Gabrielli, F, Puglisi, A, Bertolucci, A, Marchi, S, Bellini, M, Casagli, S, De Simone, B, Carmassi, F, Marchetti, S, Accorsini, M, Cremonini, C, Morelli, F, Romeo, L, Coccolini F., Kluger Y., Moore E. E., Maier R. V., Coimbra R., Ordonez C., Ivatury R., Kirkpatrick A. W., Biffl W., Sartelli M., Hecker A., Ansaloni L., Leppaniemi A., Reva V., Civil I., Vega F., Chiarugi M., Chichom-Mefire A., Sakakushev B., Peitzman A., Chiara O., Abu-Zidan F., Maegele M., Miccoli M., Chirica M., Khokha V., Sugrue M., Fraga G. P., Otomo Y., Baiocchi G. L., Catena F., Kuliesius Z., Conti L., Dogjani A., Lee J. G., Consani H., Russello D., Bortul M., Maurel T. G., Kaf H. S., Adamou H., Alin V., Robustelli U., Sato N., Seretis C., Quiodettis M., Gomes C. A., Kong V., Zakaria A. D., Guner A., Gachabayov M., Chowdhury S., Pata F., Garcia A., Rems M., Das K., Riedel J. G., Lasithiotakis K., Sydorchuk R., Sydorchuk L., Lostoridis E., Buia A., McFarlane M., Ciani R., Munoz-Cruzado V. M. D., Tartaglia D., Ioannidis O., Muhrbeck M., Reicher M., Roscio F., Ceresoli M., Tsiftsis D., Kavalakat A., Pintar T., Georgiou G., Ricci G., Mohan R., Saar S., Di Carlo I., Isik A., Ahmed A. Y. Y. M., Gonsaga R. A. T., Sammartano F., Tallon-Aguilar L., Shoko T., Hsu J., Kobe Y., Romeo C. G. L., Podda M., Mingoli A., Delgado R. C., Ekwen G., Aude V., Olona C., Boati P., Magnone S., Capaldi M., Bala M., Picetti E., Negoi I., Kok K. Y. Y., Jusoh A. C., Amato B., Nita G. E., de Beaux A., Demetrashvili Z., Davies R. J., Kim J. I., Pereira A., Fattori L., Paolillo C., Ghannam W., Rodriguez F. M., Berardi L., Florio M. G., Hecker M., Dubuisson V., O'Connor D. B., De'Angelis N., Dobric I., Massalou D., Ortenwall P., Pikoulis E., Ugarte-Sierra B., Zuidema W. P., Kechagias A., Marwah S., Litvin A., Nikolopoulos I., Pesce A., Uranues S., Luppi D., Flohe S., Martinez-Perez A., Lorenzo M., Vergano L. B., Manca M., Malacarne P., Kurihara H., Widder S., Pucciarelli M., Monzani F., Brambillasca P., Corbella D., Agresta F., Moore L., Buonomo L. A., Adeleye A. O., Kim D., Veroux M., Hardcastle T. C., Di Saverio S., Recordare A., Rubio-Perez I., Shlyapnikov S., Rahim R., Vega G. M. M., Boris K., Sawyer R., Baraket O., Soreide K., Weber C., Seak C. -J., Herman S., Gamberini E., Costa S., Mazzocconi G., Lozada E., Manatakis D., Lohsiriwat V., Ahmed A., Elbery B., Tiberio G. A. M., Santini M., Mellace L., Enoksen C. H., Major P., Parini D., Improta M., Fugazzola P., Pini S., Liberti G., Martino C., Cobianchi L., Canzi G., Cicuttin E., Kenig J., Zago M., Giannessi S., Scaglione M., Orsitto E., Cioni R., Ghiadoni L., Menichetti F., Agnoletti V., Sganga G., Prosperi P., Roviello F., De Paolis P., Gordini G., Forfori F., Ruscelli P., Gabrielli F., Puglisi A., Bertolucci A., Marchi S., Bellini M., Casagli S., De Simone B., Carmassi F., Marchetti S., Accorsini M., Cremonini C., Morelli F., Romeo L., Coccolini, F, Kluger, Y, Moore, E, Maier, R, Coimbra, R, Ordonez, C, Ivatury, R, Kirkpatrick, A, Biffl, W, Sartelli, M, Hecker, A, Ansaloni, L, Leppaniemi, A, Reva, V, Civil, I, Vega, F, Chiarugi, M, Chichom-Mefire, A, Sakakushev, B, Peitzman, A, Chiara, O, Abu-Zidan, F, Maegele, M, Miccoli, M, Chirica, M, Khokha, V, Sugrue, M, Fraga, G, Otomo, Y, Baiocchi, G, Catena, F, Kuliesius, Z, Conti, L, Dogjani, A, Lee, J, Consani, H, Russello, D, Bortul, M, Maurel, T, Kaf, H, Adamou, H, Alin, V, Robustelli, U, Sato, N, Seretis, C, Quiodettis, M, Gomes, C, Kong, V, Zakaria, A, Guner, A, Gachabayov, M, Chowdhury, S, Pata, F, Garcia, A, Rems, M, Das, K, Riedel, J, Lasithiotakis, K, Sydorchuk, R, Sydorchuk, L, Lostoridis, E, Buia, A, Mcfarlane, M, Ciani, R, Munoz-Cruzado, V, Tartaglia, D, Ioannidis, O, Muhrbeck, M, Reicher, M, Roscio, F, Ceresoli, M, Tsiftsis, D, Kavalakat, A, Pintar, T, Georgiou, G, Ricci, G, Mohan, R, Saar, S, Di Carlo, I, Isik, A, Ahmed, A, Gonsaga, R, Sammartano, F, Tallon-Aguilar, L, Shoko, T, Hsu, J, Kobe, Y, Romeo, C, Podda, M, Mingoli, A, Delgado, R, Ekwen, G, Aude, V, Olona, C, Boati, P, Magnone, S, Capaldi, M, Bala, M, Picetti, E, Negoi, I, Kok, K, Jusoh, A, Amato, B, Nita, G, de Beaux, A, Demetrashvili, Z, Davies, R, Kim, J, Pereira, A, Fattori, L, Paolillo, C, Ghannam, W, Rodriguez, F, Berardi, L, Florio, M, Hecker, M, Dubuisson, V, O'Connor, D, De'Angelis, N, Dobric, I, Massalou, D, Ortenwall, P, Pikoulis, E, Ugarte-Sierra, B, Zuidema, W, Kechagias, A, Marwah, S, Litvin, A, Nikolopoulos, I, Pesce, A, Uranues, S, Luppi, D, Flohe, S, Martinez-Perez, A, Lorenzo, M, Vergano, L, Manca, M, Malacarne, P, Kurihara, H, Widder, S, Pucciarelli, M, Monzani, F, Brambillasca, P, Corbella, D, Agresta, F, Moore, L, Buonomo, L, Adeleye, A, Kim, D, Veroux, M, Hardcastle, T, Di Saverio, S, Recordare, A, Rubio-Perez, I, Shlyapnikov, S, Rahim, R, Vega, G, Boris, K, Sawyer, R, Baraket, O, Soreide, K, Weber, C, Seak, C, Herman, S, Gamberini, E, Costa, S, Mazzocconi, G, Lozada, E, Manatakis, D, Lohsiriwat, V, Elbery, B, Tiberio, G, Santini, M, Mellace, L, Enoksen, C, Major, P, Parini, D, Improta, M, Fugazzola, P, Pini, S, Liberti, G, Martino, C, Cobianchi, L, Canzi, G, Cicuttin, E, Kenig, J, Zago, M, Giannessi, S, Scaglione, M, Orsitto, E, Cioni, R, Ghiadoni, L, Menichetti, F, Agnoletti, V, Sganga, G, Prosperi, P, Roviello, F, De Paolis, P, Gordini, G, Forfori, F, Ruscelli, P, Gabrielli, F, Puglisi, A, Bertolucci, A, Marchi, S, Bellini, M, Casagli, S, De Simone, B, Carmassi, F, Marchetti, S, Accorsini, M, Cremonini, C, Morelli, F, Romeo, L, Coccolini F., Kluger Y., Moore E. E., Maier R. V., Coimbra R., Ordonez C., Ivatury R., Kirkpatrick A. W., Biffl W., Sartelli M., Hecker A., Ansaloni L., Leppaniemi A., Reva V., Civil I., Vega F., Chiarugi M., Chichom-Mefire A., Sakakushev B., Peitzman A., Chiara O., Abu-Zidan F., Maegele M., Miccoli M., Chirica M., Khokha V., Sugrue M., Fraga G. P., Otomo Y., Baiocchi G. L., Catena F., Kuliesius Z., Conti L., Dogjani A., Lee J. G., Consani H., Russello D., Bortul M., Maurel T. G., Kaf H. S., Adamou H., Alin V., Robustelli U., Sato N., Seretis C., Quiodettis M., Gomes C. A., Kong V., Zakaria A. D., Guner A., Gachabayov M., Chowdhury S., Pata F., Garcia A., Rems M., Das K., Riedel J. G., Lasithiotakis K., Sydorchuk R., Sydorchuk L., Lostoridis E., Buia A., McFarlane M., Ciani R., Munoz-Cruzado V. M. D., Tartaglia D., Ioannidis O., Muhrbeck M., Reicher M., Roscio F., Ceresoli M., Tsiftsis D., Kavalakat A., Pintar T., Georgiou G., Ricci G., Mohan R., Saar S., Di Carlo I., Isik A., Ahmed A. Y. Y. M., Gonsaga R. A. T., Sammartano F., Tallon-Aguilar L., Shoko T., Hsu J., Kobe Y., Romeo C. G. L., Podda M., Mingoli A., Delgado R. C., Ekwen G., Aude V., Olona C., Boati P., Magnone S., Capaldi M., Bala M., Picetti E., Negoi I., Kok K. Y. Y., Jusoh A. C., Amato B., Nita G. E., de Beaux A., Demetrashvili Z., Davies R. J., Kim J. I., Pereira A., Fattori L., Paolillo C., Ghannam W., Rodriguez F. M., Berardi L., Florio M. G., Hecker M., Dubuisson V., O'Connor D. B., De'Angelis N., Dobric I., Massalou D., Ortenwall P., Pikoulis E., Ugarte-Sierra B., Zuidema W. P., Kechagias A., Marwah S., Litvin A., Nikolopoulos I., Pesce A., Uranues S., Luppi D., Flohe S., Martinez-Perez A., Lorenzo M., Vergano L. B., Manca M., Malacarne P., Kurihara H., Widder S., Pucciarelli M., Monzani F., Brambillasca P., Corbella D., Agresta F., Moore L., Buonomo L. A., Adeleye A. O., Kim D., Veroux M., Hardcastle T. C., Di Saverio S., Recordare A., Rubio-Perez I., Shlyapnikov S., Rahim R., Vega G. M. M., Boris K., Sawyer R., Baraket O., Soreide K., Weber C., Seak C. -J., Herman S., Gamberini E., Costa S., Mazzocconi G., Lozada E., Manatakis D., Lohsiriwat V., Ahmed A., Elbery B., Tiberio G. A. M., Santini M., Mellace L., Enoksen C. H., Major P., Parini D., Improta M., Fugazzola P., Pini S., Liberti G., Martino C., Cobianchi L., Canzi G., Cicuttin E., Kenig J., Zago M., Giannessi S., Scaglione M., Orsitto E., Cioni R., Ghiadoni L., Menichetti F., Agnoletti V., Sganga G., Prosperi P., Roviello F., De Paolis P., Gordini G., Forfori F., Ruscelli P., Gabrielli F., Puglisi A., Bertolucci A., Marchi S., Bellini M., Casagli S., De Simone B., Carmassi F., Marchetti S., Accorsini M., Cremonini C., Morelli F., and Romeo L.

Abstract

Introduction: Quality in medical care must be measured in order to be improved. Trauma management is part of health care, and by definition, it must be checked constantly. The only way to measure quality and outcomes is to systematically accrue data and analyze them. Material and methods: A systematic revision of the literature about quality indicators in trauma associated to an international consensus conference Results: An internationally approved base core set of 82 trauma quality indicators was obtained: Indicators were divided into 6 fields: prevention, structure, process, outcome, post-traumatic management, and society integrational effects. Conclusion: Present trauma quality indicator core set represents the result of an international effort aiming to provide a useful tool in quality evaluation and improvement. Further improvement may only be possible through international trauma registry development. This will allow for huge international data accrual permitting to evaluate results and compare outcomes.

Published
2021

23. Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia

Author

Fresa, A., Autore, F., Innocenti, I., Piciocchi, A., Tomasso, A., Morelli, F., Sora, F., Sica, S., De Stefano, V., Laurenti, L., Fresa A., Autore F., Innocenti I., Tomasso A., Morelli F., Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), De Stefano V. (ORCID:0000-0002-5178-5827), Laurenti L. (ORCID:0000-0002-8327-1396), Fresa, A., Autore, F., Innocenti, I., Piciocchi, A., Tomasso, A., Morelli, F., Sora, F., Sica, S., De Stefano, V., Laurenti, L., Fresa A., Autore F., Innocenti I., Tomasso A., Morelli F., Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), De Stefano V. (ORCID:0000-0002-5178-5827), and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Infusion-related reactions are among the worst complications of obinutuzumab (G) administration and occur predominantly during the first infusion. We reported another adverse event related to the first G infusion, a subclinical coagulopathy. We retrospectively analyzed a cohort of 13 pts with chronic lymphocytic leukemia treated with a frontline G-chlorambucil regimen. Six pts developed non-overt disseminated intravascular coagulopathy (DIC) (46%) after the first administration of G. The coagulopathy was subclinical and self-limited in all pts, not requiring any intervention apart from the suspension of anticoagulant therapy in one pt. We observed a drop in the platelet count, an elevation of D-dimer levels, and an elongation of activated partial thromboplastin time. We found a significant difference in the platelet count between the pts with DIC and those withouts; in fact, all the six pts with non-overt DIC had a platelet count greater than 100 × 109/L, while in the other group only one (p = 0.019). A trend towards a lower lymphocyte count and a higher CD20 expression was found in the pts with DIC. No other correlation between the DIC complication and the clinical or laboratory characteristics of the patients was found. The pathogenesis of the G-related non-overt DIC could be related to the consumption of the platelets after the lysis of lymphocytes, probably triggered by the damage associated molecular patterns. Despite its limitations, this study describes a new adverse event and identifies a specific subgroup of patients whose clinical management at the time of the infusion of G may need to be refined.

Published
2021

24. Trauma quality indicators: internationally approved core factors for trauma management quality evaluation

Author

Coccolini, F., Kluger, Y., Moore, E. E., Maier, R. V., Coimbra, R., Ordonez, C., Ivatury, R., Kirkpatrick, A. W., Biffl, W., Sartelli, M., Hecker, A., Ansaloni, L., Leppaniemi, A., Reva, V., Civil, I., Vega, F., Chiarugi, M., Chichom-Mefire, A., Sakakushev, B., Peitzman, A., Chiara, O., Abu-Zidan, F., Maegele, M., Miccoli, M., Chirica, M., Khokha, V., Sugrue, M., Fraga, G. P., Otomo, Y., Baiocchi, G. L., Catena, F., Kuliesius, Z., Conti, L., Dogjani, A., Lee, J. G., Consani, H., Russello, D., Bortul, M., Maurel, T. G., Kaf, H. S., Adamou, H., Alin, V., Robustelli, U., Sato, N., Seretis, C., Quiodettis, M., Gomes, C. A., Kong, V., Zakaria, A. D., Guner, A., Gachabayov, M., Chowdhury, S., Pata, F., Garcia, A., Rems, M., Das, K., Riedel, J. G., Lasithiotakis, K., Sydorchuk, R., Sydorchuk, L., Lostoridis, E., Buia, A., Mcfarlane, M., Ciani, R., Munoz-Cruzado, V. M. D., Tartaglia, D., Ioannidis, O., Muhrbeck, M., Reicher, M., Roscio, F., Ceresoli, M., Tsiftsis, D., Kavalakat, A., Pintar, T., Georgiou, G., Ricci, G., Mohan, R., Saar, S., Di Carlo, I., Isik, A., Ahmed, A. Y. Y. M., Gonsaga, R. A. T., Sammartano, F., Tallon-Aguilar, L., Shoko, T., Hsu, J., Kobe, Y., Romeo, C. G. L., Podda, M., Mingoli, A., Delgado, R. C., Ekwen, G., Aude, V., Olona, C., Boati, P., Magnone, S., Capaldi, M., Bala, M., Picetti, E., Negoi, I., Kok, K. Y. Y., Jusoh, A. C., Amato, B., Nita, G. E., de Beaux, A., Demetrashvili, Z., Davies, R. J., Kim, J. I., Pereira, A., Fattori, L., Paolillo, C., Ghannam, W., Rodriguez, F. M., Berardi, L., Florio, M. G., Hecker, M., Dubuisson, V., O'Connor, D. B., De'Angelis, N., Dobric, I., Massalou, D., Ortenwall, P., Pikoulis, E., Ugarte-Sierra, B., Zuidema, W. P., Kechagias, A., Marwah, S., Litvin, A., Nikolopoulos, I., Pesce, A., Uranues, S., Luppi, D., Flohe, S., Martinez-Perez, A., Lorenzo, M., Vergano, L. B., Manca, M., Malacarne, P., Kurihara, H., Widder, S., Pucciarelli, M., Monzani, F., Brambillasca, P., Corbella, D., Agresta, F., Moore, L., Buonomo, L. A., Adeleye, A. O., Kim, D., Veroux, M., Hardcastle, T. C., Di Saverio, S., Recordare, A., Rubio-Perez, I., Shlyapnikov, S., Rahim, R., Vega, G. M. M., Boris, K., Sawyer, R., Baraket, O., Soreide, K., Weber, C., Seak, C. -J., Herman, S., Gamberini, E., Costa, S., Mazzocconi, G., Lozada, E., Manatakis, D., Lohsiriwat, V., Ahmed, A., Elbery, B., Tiberio, G. A. M., Santini, M., Mellace, L., Enoksen, C. H., Major, P., Parini, D., Improta, M., Fugazzola, P., Pini, S., Liberti, G., Martino, C., Cobianchi, L., Canzi, G., Cicuttin, E., Kenig, J., Zago, M., Giannessi, S., Scaglione, M., Orsitto, E., Cioni, R., Ghiadoni, L., Menichetti, F., Agnoletti, V., Sganga, G., Prosperi, P., Roviello, F., De Paolis, P., Gordini, G., Forfori, F., Ruscelli, P., Gabrielli, F., Puglisi, A., Bertolucci, A., Marchi, S., Bellini, M., Casagli, S., De Simone, B., Carmassi, F., Marchetti, S., Accorsini, M., Cremonini, C., Morelli, F., Romeo, L., Coccolini F., Kluger Y., Moore E.E., Maier R.V., Coimbra R., Ordonez C., Ivatury R., Kirkpatrick A.W., Biffl W., Sartelli M., Hecker A., Ansaloni L., Leppaniemi A., Reva V., Civil I., Vega F., Chiarugi M., Chichom-Mefire A., Sakakushev B., Peitzman A., Chiara O., Abu-Zidan F., Maegele M., Miccoli M., Chirica M., Khokha V., Sugrue M., Fraga G.P., Otomo Y., Baiocchi G.L., Catena F., Kuliesius Z., Conti L., Dogjani A., Lee J.G., Consani H., Russello D., Bortul M., Maurel T.G., Kaf H.S., Adamou H., Alin V., Robustelli U., Sato N., Seretis C., Quiodettis M., Gomes C.A., Kong V., Zakaria A.D., Guner A., Gachabayov M., Chowdhury S., Pata F., Garcia A., Rems M., Das K., Riedel J.G., Lasithiotakis K., Sydorchuk R., Sydorchuk L., Lostoridis E., Buia A., McFarlane M., Ciani R., Munoz-Cruzado V.M.D., Tartaglia D., Ioannidis O., Muhrbeck M., Reicher M., Roscio F., Ceresoli M., Tsiftsis D., Kavalakat A., Pintar T., Georgiou G., Ricci G., Mohan R., Saar S., Di Carlo I., Isik A., Ahmed A.Y.Y.M., Gonsaga R.A.T., Sammartano F., Tallon-Aguilar L., Shoko T., Hsu J., Kobe Y., Romeo C.G.L., Podda M., Mingoli A., Delgado R.C., Ekwen G., Aude V., Olona C., Boati P., Magnone S., Capaldi M., Bala M., Picetti E., Negoi I., Kok K.Y.Y., Jusoh A.C., Amato B., Nita G.E., de Beaux A., Demetrashvili Z., Davies R.J., Kim J.I., Pereira A., Fattori L., Paolillo C., Ghannam W., Rodriguez F.M., Berardi L., Florio M.G., Hecker M., Dubuisson V., O'Connor D.B., De'Angelis N., Dobric I., Massalou D., Ortenwall P., Pikoulis E., Ugarte-Sierra B., Zuidema W.P., Kechagias A., Marwah S., Litvin A., Nikolopoulos I., Pesce A., Uranues S., Luppi D., Flohe S., Martinez-Perez A., Lorenzo M., Vergano L.B., Manca M., Malacarne P., Kurihara H., Widder S., Pucciarelli M., Monzani F., Brambillasca P., Corbella D., Agresta F., Moore L., Buonomo L.A., Adeleye A.O., Kim D., Veroux M., Hardcastle T.C., Di Saverio S., Recordare A., Rubio-Perez I., Shlyapnikov S., Rahim R., Vega G.M.M., Boris K., Sawyer R., Baraket O., Soreide K., Weber C., Seak C.-J., Herman S., Gamberini E., Costa S., Mazzocconi G., Lozada E., Manatakis D., Lohsiriwat V., Ahmed A., Elbery B., Tiberio G.A.M., Santini M., Mellace L., Enoksen C.H., Major P., Parini D., Improta M., Fugazzola P., Pini S., Liberti G., Martino C., Cobianchi L., Canzi G., Cicuttin E., Kenig J., Zago M., Giannessi S., Scaglione M., Orsitto E., Cioni R., Ghiadoni L., Menichetti F., Agnoletti V., Sganga G., Prosperi P., Roviello F., De Paolis P., Gordini G., Forfori F., Ruscelli P., Gabrielli F., Puglisi A., Bertolucci A., Marchi S., Bellini M., Casagli S., De Simone B., Carmassi F., Marchetti S., Accorsini M., Cremonini C., Morelli F., Romeo L., Coccolini, F, Kluger, Y, Moore, E, Maier, R, Coimbra, R, Ordonez, C, Ivatury, R, Kirkpatrick, A, Biffl, W, Sartelli, M, Hecker, A, Ansaloni, L, Leppaniemi, A, Reva, V, Civil, I, Vega, F, Chiarugi, M, Chichom-Mefire, A, Sakakushev, B, Peitzman, A, Chiara, O, Abu-Zidan, F, Maegele, M, Miccoli, M, Chirica, M, Khokha, V, Sugrue, M, Fraga, G, Otomo, Y, Baiocchi, G, Catena, F, Kuliesius, Z, Conti, L, Dogjani, A, Lee, J, Consani, H, Russello, D, Bortul, M, Maurel, T, Kaf, H, Adamou, H, Alin, V, Robustelli, U, Sato, N, Seretis, C, Quiodettis, M, Gomes, C, Kong, V, Zakaria, A, Guner, A, Gachabayov, M, Chowdhury, S, Pata, F, Garcia, A, Rems, M, Das, K, Riedel, J, Lasithiotakis, K, Sydorchuk, R, Sydorchuk, L, Lostoridis, E, Buia, A, Mcfarlane, M, Ciani, R, Munoz-Cruzado, V, Tartaglia, D, Ioannidis, O, Muhrbeck, M, Reicher, M, Roscio, F, Ceresoli, M, Tsiftsis, D, Kavalakat, A, Pintar, T, Georgiou, G, Ricci, G, Mohan, R, Saar, S, Di Carlo, I, Isik, A, Ahmed, A, Gonsaga, R, Sammartano, F, Tallon-Aguilar, L, Shoko, T, Hsu, J, Kobe, Y, Romeo, C, Podda, M, Mingoli, A, Delgado, R, Ekwen, G, Aude, V, Olona, C, Boati, P, Magnone, S, Capaldi, M, Bala, M, Picetti, E, Negoi, I, Kok, K, Jusoh, A, Amato, B, Nita, G, de Beaux, A, Demetrashvili, Z, Davies, R, Kim, J, Pereira, A, Fattori, L, Paolillo, C, Ghannam, W, Rodriguez, F, Berardi, L, Florio, M, Hecker, M, Dubuisson, V, O'Connor, D, De'Angelis, N, Dobric, I, Massalou, D, Ortenwall, P, Pikoulis, E, Ugarte-Sierra, B, Zuidema, W, Kechagias, A, Marwah, S, Litvin, A, Nikolopoulos, I, Pesce, A, Uranues, S, Luppi, D, Flohe, S, Martinez-Perez, A, Lorenzo, M, Vergano, L, Manca, M, Malacarne, P, Kurihara, H, Widder, S, Pucciarelli, M, Monzani, F, Brambillasca, P, Corbella, D, Agresta, F, Moore, L, Buonomo, L, Adeleye, A, Kim, D, Veroux, M, Hardcastle, T, Di Saverio, S, Recordare, A, Rubio-Perez, I, Shlyapnikov, S, Rahim, R, Vega, G, Boris, K, Sawyer, R, Baraket, O, Soreide, K, Weber, C, Seak, C, Herman, S, Gamberini, E, Costa, S, Mazzocconi, G, Lozada, E, Manatakis, D, Lohsiriwat, V, Elbery, B, Tiberio, G, Santini, M, Mellace, L, Enoksen, C, Major, P, Parini, D, Improta, M, Fugazzola, P, Pini, S, Liberti, G, Martino, C, Cobianchi, L, Canzi, G, Cicuttin, E, Kenig, J, Zago, M, Giannessi, S, Scaglione, M, Orsitto, E, Cioni, R, Ghiadoni, L, Menichetti, F, Agnoletti, V, Sganga, G, Prosperi, P, Roviello, F, De Paolis, P, Gordini, G, Forfori, F, Ruscelli, P, Gabrielli, F, Puglisi, A, Bertolucci, A, Marchi, S, Bellini, M, Casagli, S, De Simone, B, Carmassi, F, Marchetti, S, Accorsini, M, Cremonini, C, Morelli, F, Romeo, L, and HUS Abdominal Center

Subjects
System, Consensus, Internationality, Delphi Technique, Accrual, Process (engineering), media_common.quotation_subject, Performance, education, lcsh:Surgery, 030230 surgery, Analysis, Data, Morbidity, Mortality, Outcome, Planning, Product, World, 03 medical and health sciences, 0302 clinical medicine, Trauma management, Health care, Medicine, Humans, Operations management, Quality (business), Product (category theory), media_common, Quality Indicators, Health Care, Core set, business.industry, lcsh:Medical emergencies. Critical care. Intensive care. First aid, Analysi, lcsh:RD1-811, lcsh:RC86-88.9, CARE, 3126 Surgery, anesthesiology, intensive care, radiology, Core (game theory), Traumatology, Emergency Medicine, Surgery, business, Research Article
Abstract

Introduction Quality in medical care must be measured in order to be improved. Trauma management is part of health care, and by definition, it must be checked constantly. The only way to measure quality and outcomes is to systematically accrue data and analyze them. Material and methods A systematic revision of the literature about quality indicators in trauma associated to an international consensus conference Results An internationally approved base core set of 82 trauma quality indicators was obtained: Indicators were divided into 6 fields: prevention, structure, process, outcome, post-traumatic management, and society integrational effects. Conclusion Present trauma quality indicator core set represents the result of an international effort aiming to provide a useful tool in quality evaluation and improvement. Further improvement may only be possible through international trauma registry development. This will allow for huge international data accrual permitting to evaluate results and compare outcomes.

Published
2021

25. Erratum: ☆Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006))

Author

Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

The authors regret that the affiliation of Drs. Barone and De. Giorgi in the Acknowledgements section is incorrect and should be as follows: Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. Barone and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. De Giorgi and The authors would like to apologise for any inconvenience caused.

Published
2020

26. Erratum: ☆Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006))

Author

Banna G. L., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna G. L., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, Da Pozzo, L, Di Nardo, D, Fornarini, G, Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., Da Pozzo L., Di Nardo D., Fornarini G., Galetti T. P., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

The authors regret that the affiliation of Drs. Barone and De. Giorgi in the Acknowledgements section is incorrect and should be as follows: Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. Barone and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy for Dr. De Giorgi and The authors would like to apologise for any inconvenience caused.

Published
2020

27. Large-scale spatial variability in urban tolerance of birds

Author

Callaghan, C.T., Palacio, F.X., Benedetti, Y., Morelli, F., Bowler, Diana, Callaghan, C.T., Palacio, F.X., Benedetti, Y., Morelli, F., and Bowler, Diana

Abstract

Quantifying intraspecific and interspecific trait variability is critical to our understanding of biogeography, ecology and conservation. But quantifying such variability and understanding the importance of intraspecific and interspecific variability remain challenging. This is especially true of large geographic scales as this is where the differences between intraspecific and interspecific variability are likely to be greatest.Our goal is to address this research gap using broad-scale citizen science data to quantify intraspecific variability and compare it with interspecific variability, using the example of bird responses to urbanization across the continental United States.Using more than 100 million observations, we quantified urban tolerance for 338 species within randomly sampled spatial regions and then calculated the standard deviation of each species' urban tolerance.We found that species' spatial variability in urban tolerance (i.e. standard deviation) was largely explained by the variability of urban cover throughout a species' range (R2 = 0.70). Variability in urban tolerance was greater in species that were more tolerant of urban cover (i.e. the average urban tolerance throughout their range), suggesting that generalist life histories are better suited to adapt to novel anthropogenic environments. Overall, species differences explained most of the variability in urban tolerance across spatial regions.Together, our results indicate that (1) intraspecific variability is largely predicted by local environmental variability in urban cover at a large spatial scale and (2) interspecific variability is greater than intraspecific variability, supporting the common use of mean values (i.e. collapsing observations across a species' range) when assessing species–environment relationships. Further studies, across different taxa, traits and species–environment relationships are needed to test the role of intraspecific variability, but nevertheles

Published
2022

28. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

Author

Ghi, M. G., Paccagnella, A., Ferrari, D., Foa, P., Alterio, D., Codecà, C., Nolè, F., Verri, E., Orecchia, R., Morelli, F., Parisi, S., Mastromauro, C., Mione, C. A., Rossetto, C., Polsinelli, M., Koussis, H., Loreggian, L., Bonetti, A., Campostrini, F., Azzarello, G., D’Ambrosio, C., Bertoni, F., Casanova, C., Emiliani, E., Guaraldi, M., Bunkheila, F., Bidoli, P., Niespolo, R. M., Gava, A., Massa, E., Frattegiani, A., Valduga, F., Pieri, G., Cipani, T., Da Corte, D., Chiappa, F., and Rulli, E.

Published
2017
Full Text
View/download PDF

29. Redefining the zoning of active and capable faults in urban areas: the case of the Mt. Marine fault across the Barete and Pizzoli towns (Central Apennines, Italy)

Author

Iezzi, F., Boncio, P., Pizzi, A., Piacentini, T., Pace, B., Francescone, M., Morelli, F., Puliti, I., Salvatore, N., Blumetti, A., Di Manna, P., Papasodaro, F., Moro, M., Falcucci, E., Gori, S., Saroli, M., Nicolosi, I., D’Ajello Caracciolo, F., Chiappini, M., Sapia, V., Materni, V., Urbini, S., Caciagli, M., Di Giulio, G., Vassallo, M., Milana, G., Minarelli, L., Pischiutta, M., Cara, F., Sepe, V., and Doglioni, C.

Published
2022

33. Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica

Author

Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, DA POZZO, L, Di Nardo, D, Fornarini, G, Prayer Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., DA POZZO, LUIGI FILIPPO, Di Nardo D., Fornarini G., Prayer Galetti T., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., De Giorgi U., Banna, G, Nicolai, N, Palmieri, G, Ottaviano, M, Balzarini, L, Barone, D, Basso, U, Bavila, A, Bertoni, F, Calliada, F, Cai, T, Carrafiello, G, Condello, C, DA POZZO, L, Di Nardo, D, Fornarini, G, Prayer Galetti, T, Garolla, A, Giannatempo, P, Guerra, L, La Spina, S, Malatino, L, Marchiano', A, Monti, M, Morbiato, F, Morelli, F, Nole', F, Palazzi, S, Procopio, G, Rosti, G, Sacco, C, Salvetti, A, Salvioni, R, Sava, T, Secondino, S, Serpentini, S, Spreafico, C, Tavolini, I, Valcamonico, F, Verri, E, Zucali, P, De Giorgi, U, Banna G. L., Nicolai N., Palmieri G., Ottaviano M., Balzarini L., Barone D., Basso U., Bavila A., Bertoni F., Calliada F., Cai T., Carrafiello G., Condello C., DA POZZO, LUIGI FILIPPO, Di Nardo D., Fornarini G., Prayer Galetti T., Garolla A., Giannatempo P., Guerra L., La Spina S., Malatino L., Marchiano' A., Monti M., Morbiato F. F., Morelli F., Nole' F., Palazzi S., Procopio G., Rosti G., Sacco C., Salvetti A., Salvioni R., Sava T., Secondino S., Serpentini S., Spreafico C., Tavolini I. M., Valcamonico F., Verri E., Zucali P., and De Giorgi U.

Abstract

Background: No compelling evidence is available about surveillance and follow-up of patients with testicular germ cell tumour (TGCT). Methods: In the light of the best clinical evidence, the Italian Germ cell cancer Group (IGG) and the Associazione Italiana di Oncologia Medica (AIOM) set up a multidisciplinary national consensus conference, involving 42 leading experts and 3 TGCT survivors. A minimum of 50% of votes was required in order to achieve a consensus recommendation on 29 questions. Results: Recommendations have been summarized in three tables, divided by stage I seminoma, stage I nonseminoma and the advanced disease, which may be useful for clinicians to appropriately choose the clinical investigation and its timing during the surveillance and follow-up of TGCT patients based on an accurate estimation of their risk of disease relapse. Conclusions: The IGG-AIOM consensus recommendations may help clinicians to choose appropriate clinical investigations for the surveillance and follow-up of TGCT patients.

Published
2019

35. Apomorphine-induced reorganization of striato-frontal connectivity in patients with tremor-dominant Parkinson's disease

Author

Salvatore Nigro* a, Cécile Bordier* b, i, Antonio Cerasa c, Rita Nisticò c, Giuseppe Olivadese c, Basilio Vescio d, Maria Giovanna Bianco e, Antonino Fiorillo e, Gaetano Barbagallo f, Marianna Crasà c, Andrea Quattrone f, Maurizio Morelli f, Gennarina Arabia f, Antonio Augimeri d, Carlo Nicolini b, Angelo Bifone b, g, Aldo Quattrone c, and h

Subjects
Male, 0301 basic medicine, Levodopa, Parkinson's disease, Apomorphine, Dopamine agonist, Resting-state, 03 medical and health sciences, fMRI Graph theory, 0302 clinical medicine, Neural Pathways, Tremor, Basal ganglia, medicine, Humans, Single-Blind Method, Resting-state fMRI, Aged, Tremor-dominant Parkinson's disease, Neural correlates of consciousness, Community detection, Graph theory, Resting state fMRI, medicine.diagnostic_test, Electromyography, business.industry, Functional Neuroimaging, Parkinson Disease, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Frontal Lobe, 3. Good health, Neostriatum, 030104 developmental biology, Neurology, Dopamine Agonists, Female, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience, 030217 neurology & neurosurgery, medicine.drug
Abstract

Introduction Apomorphine is a dopamine agonist used in Parkinson's disease (PD), which matches levodopa in terms of the magnitude of effect on the cardinal motor features, such as tremor and bradykinesia. The beneficial effect of this treatment on PD patients with tremor-dominant has widely been demonstrated, although the underlying neural correlates are unknown. We sought to examine the effects of apomorphine on topological characteristics of resting-state functional connectivity networks in tremor-dominant PD (tdPD) patients. Methods Sixteen tdPD patients were examined using a combined electromyography-functional magnetic resonance imaging approach. Patients were scanned twice following either placebo (subcutaneous injection of 1 mL saline solution) or 1 mg of apomorphine injection. Graph analysis methods were employed to investigate the modular organization of functional connectivity networks before and after drug treatment. Results After injection of apomorphine, evident reduction of tremor symptoms was mirrored by a significant increase in overall connectivity strength and reorganization of the modular structure of the basal ganglia and of the fronto-striatal module. Moreover, we found an increase in the centrality of motor and premotor regions. No differences were found between pre- and post-placebo sessions. Conclusion These results provide new evidence about the effects of apomorphine at a large-scale neural network level showing that drug treatment modifies the brain functional organization of tdPD, increasing the overall resting-state functional connectivity strength, the segregation of striato-frontal regions and the integrative role of motor areas.

Published
2019

36. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Author

Bracarda, S., Iacovelli, R., Boni, L., Rizzo, M., Derosa, L., Rossi, M., Galli, L., Procopio, G., Sisani, M., Longo, F., Santoni, M., Morelli, F., Di Lorenzo, G., Altavilla, A., Porta, C., Camerini, A., Escudier, B., Martignetti, Angelo, Ricotta, Riccardo, Gasparro, Donatello, Sabbatini, Roberto, Ceresoli, Giovanni Luca, Mosca, Alessandra, Santini, Daniele, Caserta, Claudia, Cavanna, Luigi, Massari, Francesco, Sava, Teodoro, Boni, Corrado, Verzoni, Elena, Cartenì, Giacomo, and Hamzaj, Alketa

Published
2015
Full Text
View/download PDF

38. Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia

Author

Fresa, Alberto, Autore, Francesco, Innocenti, Idanna, Piciocchi, A., Tomasso, Annamaria, Morelli, F., Sora', Federica, Sica, Simona, De Stefano, Valerio, Laurenti, Luca, Fresa A., Autore F., Innocenti I., Tomasso A., Sica S. (ORCID:0000-0003-2426-3465), De Stefano V. (ORCID:0000-0002-5178-5827), Laurenti L. (ORCID:0000-0002-8327-1396), Fresa, Alberto, Autore, Francesco, Innocenti, Idanna, Piciocchi, A., Tomasso, Annamaria, Morelli, F., Sora', Federica, Sica, Simona, De Stefano, Valerio, Laurenti, Luca, Fresa A., Autore F., Innocenti I., Tomasso A., Sica S. (ORCID:0000-0003-2426-3465), De Stefano V. (ORCID:0000-0002-5178-5827), and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Infusion-related reactions are among the worst complications of obinutuzumab (G) administration and occur predominantly during the first infusion. We reported another adverse event related to the first G infusion, a subclinical coagulopathy. We retrospectively analyzed a cohort of 13 pts with chronic lymphocytic leukemia treated with a frontline G-chlorambucil regimen. Six pts developed non-overt disseminated intravascular coagulopathy (DIC) (46%) after the first administration of G. The coagulopathy was subclinical and self-limited in all pts, not requiring any intervention apart from the suspension of anticoagulant therapy in one pt. We observed a drop in the platelet count, an elevation of D-dimer levels, and an elongation of activated partial thromboplastin time. We found a significant difference in the platelet count between the pts with DIC and those withouts; in fact, all the six pts with non-overt DIC had a platelet count greater than 100 × 109/L, while in the other group only one (p = 0.019). A trend towards a lower lymphocyte count and a higher CD20 expression was found in the pts with DIC. No other correlation between the DIC complication and the clinical or laboratory characteristics of the patients was found. The pathogenesis of the G-related non-overt DIC could be related to the consumption of the platelets after the lysis of lymphocytes, probably triggered by the damage associated molecular patterns. Despite its limitations, this study describes a new adverse event and identifies a specific subgroup of patients whose clinical management at the time of the infusion of G may need to be refined.

Published
2021

39. Management of cerebrospinal fluid leak: The importance of multidisciplinary approach

Author

Galli, Jacopo, Morelli, Francesco, Rigante, Mario, Paludetti, Gaetano, Galli J. (ORCID:0000-0001-6353-6249), Morelli F., Rigante M. (ORCID:0000-0002-6111-0786), Paludetti G. (ORCID:0000-0003-2480-1243), Galli, Jacopo, Morelli, Francesco, Rigante, Mario, Paludetti, Gaetano, Galli J. (ORCID:0000-0001-6353-6249), Morelli F., Rigante M. (ORCID:0000-0002-6111-0786), and Paludetti G. (ORCID:0000-0003-2480-1243)

Abstract

Cerebrospinal fluid (CSF) leak remains a rare condition, characterized by serious complications and potentially fatal. According to different etiologies, CSF leaks may be classi-fied into two main categories: traumatic and spontaneous. Spontaneous fistulas seem to be mainly related to obesity and idiopathic intracranial hypertension. Diagnosis is both clinical and radiological. During the last three decades, surgical treatment has mostly shifted to endonasal endoscopic approach, which widely demonstrated to be more effective than invasive intracranial ones. Post-operative complications, long-term sequelae and hospital stay are strongly reduced thanks to endoscopic approach. The diagnosis and treatment of CSF leaks represent a difficult and challenge task. The main effort seems to be related to the precise localization of the leak. An accurate assessment of both predisposing factors and comorbidities is mandatory in case of spontaneous leaks. However, a clinical multidiscipli-nary evaluation as well as treatment, is essential to decrease the rate of failure of surgery. The presence of a dedicated instruments, the Skull Base Team, the knowledge of recon-structive materials and techniques represents a decisive result in therapeutical management even if for each patient an effective therapeutic algorithm can be obtained considering the correct leak detection and characteristics. In conclusion the strict teamwork with neurosur-geons, neuroradiologists, ophtalmologists will enable the development also of innovative biomaterials, which could spread and standardize multi-layer techniques, nowadays still related to surgeon preferences.

Published
2021

42. Multi-level approach for the assessment of bridges and viaducts within road networks

Author

Braga, F., Buratti, G., Cosentino, A., Dall'Asta, A., De Matteis, G., Gigliotti, R., Mezzina, M., Morelli, F., Ristori, C., Salvatore, W., Franco Braga, Andrea Dall'Asta, Fabrizio Gara, Braga, F., Buratti, G., Cosentino, A., Dall'Asta, A., De Matteis, G., Gigliotti, R., Mezzina, M., Morelli, F., Ristori, C., and Salvatore, W.

Published
2019

43. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Powles, T. van der Heijden, M.S. Castellano, D. Galsky, M.D. Loriot, Y. Petrylak, D.P. Ogawa, O. Park, S.H. Lee, J.-L. De Giorgi, U. Bögemann, M. Bamias, A. Eigl, B.J. Gurney, H. Mukherjee, S.D. Fradet, Y. Skoneczna, I. Tsiatas, M. Novikov, A. Suárez, C. Fay, A.P. Duran, I. Necchi, A. Wildsmith, S. He, P. Angra, N. Gupta, A.K. Levin, W. Bellmunt, J. van der Heijden, M.S. Lee, J.L. Eigl, B.J. Mukherjee, S.D. Suarez, C. Westgeest, H. Flechon, A. Ou, Y.-C. Park, I. Matveev, V. Pérez-Valderrama, B. Cheng, S. Frank, S. Anido, U. Hamzaj, A. Retz, M. Sridhar, S. Scagliotti, G.V. Voortman, J. Alekseev, B. Alyasova, A. Komyakov, B. Dumez, H. Pavic, M. Kimura, G. Mizokami, A. Osanto, S. Arranz, J.A. Piersma, D. Shin, S.J. Karyakin, O. Delgado, I. Gonzalez, J.L. Pang, S.-T. Tran, A. Lipatov, O. Su, W.-P. Flaig, T. Alva, A. Park Kyong, H. Kopyltsov, E. Almagro, E. Domenech, M. Chang, Y.-H. Sautois, B. Ravaux, A. Aravantinos, G. Georgoulias, V. Mulder, S. Kim, Y.J. Kater, F. Chevreau, C. Tagawa, S. Zalewski, P. Joly, F. Hatiboglu, G. Gianni, L. Morelli, F. Tambaro, R. Hashimoto, Y. Nosov, A. Font, A. Rodriguez-Vida, A.M. Jones, R. Vasudev, N. Srinivas, S. Zhang, J. Gil, T. Finch, D. Grimm, M.-O. Su, Y.-L. Chowdhury, S. Hocking, C. Plas, E. North, S. Jensen, N.V. Theodore, C. Imkamp, F. Peer, A. Kobayashi, T. Sakai, H. Sassa, N. Yoshimura, K. Aarts, M. Ferreira Castro, A. Topuzov, M. Rodriguez, J.F. Vazquez, F.J. Tsai, Y.-C. Crabb, S. Hussain, S. Bendell, J. Gross-Goupil, M. Gwenaelle, G. Berger, R. Statsenko, G. Evans, L. Drakaki, A. Somer, B. Davis, I. Lynam, J. Borges, G. Dettino, A. Fay, A.P. Martins, G. Zucca, L.E. Agerbaek, M. Kalofonos, H. Rosenbaum, E. Enokida, H. Kikukawa, H. Nishimura, K. Tamada, S. Uemura, M. Lopez, Y. Gietema, J. Slojewski, M. Fernandes, I. Smolin, A. Mazhar, D. Kalebasty, A.R. Carthon, B. Loidl, W. Franke, F. Girotto, G. Alimohamed, N. Macfarlane, R. Pappot, H. Niegisch, G. Mavroudis, D. Sella, A. Porta, C. Ebara, S. Nakamura, M. Obara, W. Okuno, N. Shinohara, N. Sugimoto, M. Suzuki, A. Tokuda, N. Uemura, H. Yamaguchi, A. Ramirez, F. Rozanowski, P. Wiechno, P. Keam, B. Kislov, N. Plaksin, D. Cicin, I. Kumar, S. Galsky, M.D. Petrylak, D.P. Rosales, J. Vaishampayan, U. Culine, S. Papandreou, C. Nara, T. Erman, M. Kreiger, L. Janoski, J. Rosa, D. Siqueira, M. Canil, C. Sengelov, L. Tourani, J.-M. Arai, G. Hashine, K. Kawakita, M. Nakaigawa, N. Nomi, H. Shiina, H. Suzuki, H. Yonese, J. Kuri, R. Macedo, E. Rivera, S. Villalobos Prieto, A. Polakiewicz-Gilowska, A. Zaucha, R. Lopes, F. Ponomarev, R. Pomerantz, M. Shariat, S. Luk, C. Lesniewski-Kmak, K.

Abstract

Background: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma. Methods: DANUBE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma, conducted at 224 academic research centres, hospitals, and oncology clinics in 23 countries. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1. We randomly assigned patients (1:1:1) to receive durvalumab monotherapy (1500 mg) administered intravenously every 4 weeks; durvalumab (1500 mg) plus tremelimumab (75 mg) administered intravenously every 4 weeks for up to four doses, followed by durvalumab maintenance (1500 mg) every 4 weeks; or standard-of-care chemotherapy (gemcitabine plus cisplatin or gemcitabine plus carboplatin, depending on cisplatin eligibility) administered intravenously for up to six cycles. Randomisation was done through an interactive voice–web response system, with stratification by cisplatin eligibility, PD-L1 status, and presence or absence of liver metastases, lung metastases, or both. The coprimary endpoints were overall survival compared between the durvalumab monotherapy versus chemotherapy groups in the population of patients with high PD-L1 expression (the high PD-L1 population) and between the durvalumab plus tremelimumab versus chemotherapy groups in the intention-to-treat population (all randomly assigned patients). The study has completed enrolment and the final analysis of overall survival is reported. The trial is registered with ClinicalTrials.gov, NCT02516241, and the EU Clinical Trials Register, EudraCT number 2015-001633-24. Findings: Between Nov 24, 2015, and March 21, 2017, we randomly assigned 1032 patients to receive durvalumab (n=346), durvalumab plus tremelimumab (n=342), or chemotherapy (n=344). At data cutoff (Jan 27, 2020), median follow-up for survival was 41·2 months (IQR 37·9–43·2) for all patients. In the high PD-L1 population, median overall survival was 14·4 months (95% CI 10·4–17·3) in the durvalumab monotherapy group (n=209) versus 12·1 months (10·4–15·0) in the chemotherapy group (n=207; hazard ratio 0·89, 95% CI 0·71–1·11; p=0·30). In the intention-to-treat population, median overall survival was 15·1 months (13·1–18·0) in the durvalumab plus tremelimumab group versus 12·1 months (10·9–14·0) in the chemotherapy group (0·85, 95% CI 0·72–1·02; p=0·075). In the safety population, grade 3 or 4 treatment-related adverse events occurred in 47 (14%) of 345 patients in the durvalumab group, 93 (27%) of 340 patients in the durvalumab plus tremelimumab group, and in 188 (60%) of 313 patients in the chemotherapy group. The most common grade 3 or 4 treatment-related adverse event was increased lipase in the durvalumab group (seven [2%] of 345 patients) and in the durvalumab plus tremelimumab group (16 [5%] of 340 patients), and neutropenia in the chemotherapy group (66 [21%] of 313 patients). Serious treatment-related adverse events occurred in 30 (9%) of 345 patients in the durvalumab group, 78 (23%) of 340 patients in the durvalumab plus tremelimumab group, and 50 (16%) of 313 patients in the chemotherapy group. Deaths due to study drug toxicity were reported in two (1%) patients in the durvalumab group (acute hepatic failure and hepatitis), two (1%) patients in the durvalumab plus tremelimumab group (septic shock and pneumonitis), and one (

Published
2020

45. Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape

Author

Morelli, F, Innocenti, I, Autore, F, Fresa, F, Tomasso, A, Piciocchi, A, Frustaci, Am, Trentin, L, Mauro, Fr, Schiattone, L, Visentin, A, Del Poeta, G, Reda, G, Rigolin, Gm, Ibatici, A, Ciolli, S, Vitale, C, Sportoletti, P, Murru, R, Levato, L, Gentile, M, D’Arena, G, Coscia, M, Villa, Mr, Fontana, R, Efremov, D, Tedeschi, A, Scarfò, L, Cuneo, A, Foà, R, and Laurenti, L

Published
2020

47. Endovascular Treatment of Acute Posttransplant Portal Vein Thrombosis Due to Portal Steal From Mesocaval And Coronary Portosystemic Shunts

Author

Centonze, L, Di Sandro, S, Cereda, M, Lauterio, A, De Carlis, R, Migliorisi, C, Morelli, F, Rampoldi, A, De Carlis, L, Centonze, Leonardo, Di Sandro, Stefano, Cereda, Marco, Lauterio, Andrea, De Carlis, Riccardo, Migliorisi, Carmelo, Morelli, Francesco, Rampoldi, Antonio, De Carlis, Luciano, Centonze, L, Di Sandro, S, Cereda, M, Lauterio, A, De Carlis, R, Migliorisi, C, Morelli, F, Rampoldi, A, De Carlis, L, Centonze, Leonardo, Di Sandro, Stefano, Cereda, Marco, Lauterio, Andrea, De Carlis, Riccardo, Migliorisi, Carmelo, Morelli, Francesco, Rampoldi, Antonio, and De Carlis, Luciano

Abstract

The management of portosystemic shunts in liver transplant recipients relies on appropriate perioperative study. There are several strategies for shunt handling, ranging from preoperative interventional procedures to intraoperative surgical interruption or embolization. Appropriate management often results in a successful outcome, although wrong decisions could lead to serious consequences. Here, we report a liver transplant recipient with grade 2 portal vein thrombosis associated with 2 large portosystemic shunts (coronary and mesocaval), which were managed intraoperatively via thrombectomy without shunt ligation. Acute portal vein thrombosis developed early after transplant due to portal steal syndrome. The patient underwent a successful endovascular shunt embolization, with prompt restoration of hepatopetal portal flow and resolution of the portal steal. Use of interventional radiology in perioperative management of transplant patients has recently gained wider importance; our case reported here is particularly suggestive of the good outcomes of a multidisciplinary approach to a threatening complication such as postoperative acute portal vein thrombosis.

Published
2020

48. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

Author

Mennitto, A., primary, Verzoni, E., additional, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V. E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Claps, M., additional, Guadalupi, V., additional, Sepe, P., additional, Cappelletti, V., additional, de Braud, F. G., additional, and Procopio, G., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results